Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001437749-25-020569
Filing Date
2025-06-16
Accepted
2025-06-16 21:03:32
Documents
2
Period of Report
2025-06-13

Document Format Files

Seq Description Document Type Size
1 FORM 4 rdgdoc.html 4  
1 FORM 4 rdgdoc.xml 4 5479
2 wheadon_poa.htm EX-24 8277
  Complete submission text file 0001437749-25-020569.txt   15539
Mailing Address 170 HARBOR WAY, SUITE 300 SOUTH SAN FRANCISCO CA 94080
Business Address 170 HARBOR WAY, SUITE 300 SOUTH SAN FRANCISCO CA 94080 (650) 550-3500
Vaxart, Inc. (Issuer) CIK: 0000072444 (see all company filings)

EIN.: 591212264 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O ASSERTIO THERAPEUTICS, INC. 100 SOUTH SAUNDERS ROAD, SUITE 300 LAKE FOREST IL 60045
Business Address
Wheadon David E. (Reporting) CIK: 0001789507 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-35285 | Film No.: 251051696